Skip to main content
SpringerLink
Log in

Glioblastoma Cancer Stem Cells: Response to Epidermal Growth Factor Receptor Kinase Inhibitors

  • Chapter
  • First Online:
Tumors of the Central Nervous System, Volume 1

Part of the book series: Tumors of the Central Nervous System ((TCNS,volume 1))

  • 1835 Accesses

Abstract

Glioblastoma (GBM) is the most common and aggressive neoplasia of the central nervous system in adults. Despite continued improvements in surgery, chemotherapy, and radiotherapy, clinical outcome is still dismal and better understanding of GBM biology is needed to develop novel therapies. Recent studies have demonstrated the existence of a small subpopulation of cells with stem-like features termed cancer stem cells (CSCs) in several human cancers, including GBM. CSCs are slow growing, self-renewable and highly tumorigenic, give rise to progeny of multiple lineages, and are chemo-radio-resistant, often expressing high levels of multidrug resistance and drug efflux genes. According to CSC hypothesis, current therapies are cytotoxic to the bulk of highly proliferative tumor cells but fail to kill the relatively quiescent and resistant CSC subpopulation, thus allowing these cells to survive and induce tumor recurrence. These characteristics allow GBM CSCs to survive cytotoxic therapies and drive tumor recurrence. The epidermal growth factor receptor (EGFR/HER1) belongs to the receptor tyrosine kinase (TK) family that regulates cell proliferation, survival, differentiation and motility. Overexpression of EGFR occurs in several tumors, including GBM, correlates with increased cell proliferation, decreased apoptosis, and a poorer prognosis, sustaining cancer development and progression. Small-molecules targeting EGFR-TK (TK inhibitors, TKIs) are the most clinically developed EGFR targeted-therapies for the treatment of GBM. We reported that cultures enriched in CSC isolated from human GBMs undergo growth arrest and cell death in the presence of EGFR-TKIs. The high incidence of EGFR overexpression, amplification or co-expression of the mutated, constitutively active EGFRvIII in GBMs raised expectations that treatment with EGFR TKIs, such as gefitinib or erlotinib, would have significant positive effects. This review summarizes current knowledge regarding EGFR molecular abnormalities and dysregulation in high-grade gliomas, the role of CSCs in GBM, and discusses the implications of the CSC hypothesis for the development of future EGFR-targeted therapies for brain tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Bao S, Wu Q, Mclendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444:756–760

    Article  PubMed  CAS  Google Scholar 

  • Barnes CJ, Bagheri-Yarmand R, Mandal M, Yang Z, Clayman GL, Hong WK, Kumar R (2003) Suppression of epidermal growth factor receptor, mitogen-activated protein kinase, and pak1 pathways and invasiveness of human cutaneous squamous cancer cells by the tyrosine kinase inhibitor ZD1839 (iressa). Mol Cancer 2:345–351

    CAS  Google Scholar 

  • Bax DA, Gaspar N, Little SE, Marshall L, Perryman L, Regairaz M, Viana-Pereira M, Vuononvirta R, Sharp SY, Reis-Filho JS, Stavale JN, Al-Sarraj S, Reis RM, Vassal G, Pearson AD, Hargrave D, Ellison DW, Workman P, Jones C (2009) Egfrviii deletion mutations in pediatric high-grade glioma and response to targeted therapy in pediatric glioma cell lines. Clin Cancer Res 15:5753–5761

    Article  PubMed  CAS  Google Scholar 

  • Brown PD, Krishnan S, Sarkaria JN, Wu W, Jaeckle KA, Uhm JH, Geoffroy FJ, Arusell R, Kitange G, Jenkins RB, Kugler JW, Morton RF, Rowland KM, Buckner JC (2008) Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: north central cancer treatment group study N0177. J Clin Oncol 26:5603–5609

    Article  PubMed  CAS  Google Scholar 

  • Cappuzzo F (2005) Erlotinib in gliomas: should selection be based on EGFR and akt analyses?. J Natl Cancer Inst 97:868–869

    Article  PubMed  CAS  Google Scholar 

  • Citri A, Yarden Y (2006) EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 7:505–516

    Article  PubMed  CAS  Google Scholar 

  • Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, Hahn WC, Ligon KL, Louis DN, Brennan C, Chin L, Depinho RA, Cavenee WK (2007) Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 21:2683–2710

    Article  PubMed  CAS  Google Scholar 

  • Griffero F, Daga A, Marubbi D, Capra MC, Melotti A, Pattarozzi A, Gatti M, Bajetto A, Porcile C, Barbieri F, Favoni RE, Lo Casto M, Zona G, Spaziante R, Florio T, Corte G (2009) Different response of human glioma tumor-initiating cells to epidermal growth factor receptor kinase inhibitors. J Biol Chem 284:7138–7148

    Article  PubMed  CAS  Google Scholar 

  • Gschwind A, Fischer OM, Ullrich A (2004) The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer 4:361–370

    Article  PubMed  CAS  Google Scholar 

  • Haas-Kogan DA, Prados MD, Tihan T, Eberhard DA, Jelluma N, Arvold ND, Baumber R, Lamborn KR, Kapadia A, Malec M, Berger MS, Stokoe D (2005) Epidermal growth factor receptor, protein kinase B/akt, and glioma response to erlotinib. J Natl Cancer Inst 97:880–887

    Article  PubMed  CAS  Google Scholar 

  • Hadjipanayis CG, Van Meir EG (2009) Tumor initiating cells in malignant gliomas: biology and implications for therapy. J Mol Med 87:363–374

    Article  PubMed  Google Scholar 

  • Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57–70

    Article  PubMed  CAS  Google Scholar 

  • Hegi ME, Diserens AC, Gorlia T, Hamou MF, De Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003

    Article  PubMed  CAS  Google Scholar 

  • Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, Chan KW, Ciceri P, Davis MI, Edeen PT, Faraoni R, Floyd M, Hunt JP, Lockhart DJ, Milanov ZV, Morrison MJ, Pallares G, Patel HK, Pritchard S, Wodicka LM, Zarrinkar PP (2008) A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 26:127–132

    Article  PubMed  CAS  Google Scholar 

  • Karpel-Massler G, Schmidt U, Unterberg A, Halatsch ME (2009) Therapeutic inhibition of the epidermal growth factor receptor in high-grade gliomas: where do we stand?. Mol Cancer Res 7:1000–1012

    Article  PubMed  CAS  Google Scholar 

  • Kern SE, Shibata D (2007) The fuzzy math of solid tumor stem cells: a perspective. Cancer Res 67:8985–8988

    Article  PubMed  CAS  Google Scholar 

  • Lassman AB, Rossi MR, Raizer JJ, Abrey LE, Lieberman FS, Grefe CN, Lamborn K, Pao W, Shih AH, Kuhn JG, Wilson R, Nowak NJ, Cowell JK, Deangelis LM, Wen P, Gilbert MR, Chang S, Yung WA, Prados M, Holland EC (2005) Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from north american brain tumor consortium trials 01-03 and 00-01. Clin Cancer Res 11:7841–7850

    Article  PubMed  CAS  Google Scholar 

  • Lee JC, Vivanco I, Beroukhim R, Huang JH, Feng WL, Debiasi RM, Yoshimoto K, King JC, Nghiemphu P, Yuza Y, Xu Q, Greulich H, Thomas RK, Paez JG, Peck TC, Linhart DJ, Glatt KA, Getz G, Onofrio R, Ziaugra L, Levine RL, Gabriel S, Kawaguchi T, O’neill K, Khan H, Liau LM, Nelson SF, Rao PN, Mischel P, Pieper RO, Cloughesy T, Leahy DJ, Sellers WR, Sawyers CL, Meyerson M, Mellinghoff IK (2006) Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med 3:e485

    Article  PubMed  Google Scholar 

  • Loew S, Schmidt U, Unterberg A, Halatsch ME (2009) The epidermal growth factor receptor as a therapeutic target in glioblastoma multiforme and other malignant neoplasms. Anticancer Agents Med Chem 9:703–715

    PubMed  CAS  Google Scholar 

  • Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, Lu KV, Yoshimoto K, Huang JH, Chute DJ, Riggs BL, Horvath S, Liau LM, Cavenee WK, Rao PN, Beroukhim R, Peck TC, Lee JC, Sellers WR, Stokoe D, Prados M, Cloughesy TF, Sawyers CL, Mischel PS (2005) Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353:2012–2024

    Article  PubMed  CAS  Google Scholar 

  • Mendelsohn J, Baselga J (2003) Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 21:2787–2799

    Article  PubMed  CAS  Google Scholar 

  • Mendelsohn J, Baselga J (2006) Epidermal growth factor receptor targeting in cancer. Semin Oncol 33:369–385

    Article  PubMed  CAS  Google Scholar 

  • Narita Y, Nagane M, Mishima K, Huang HJ, Furnari FB, Cavenee WK (2002) Mutant epidermal growth factor receptor signaling down-regulates P27 through activation of the phosphatidylinositol 3-kinase/akt pathway in glioblastomas. Cancer Res 62:6764–6769

    PubMed  CAS  Google Scholar 

  • Pan MG, Florio T, Stork PJ (1992) G protein activation of a hormone-stimulated phosphatase in human tumor cells. Science 256:1215–1217

    Article  PubMed  CAS  Google Scholar 

  • Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, Mardis E, Kupfer D, Wilson R, Kris M, Varmus H (2004) EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101:13306–13311

    Article  PubMed  CAS  Google Scholar 

  • Prados MD, Chang SM, Butowski N, Deboer R, Parvataneni R, Carliner H, Kabuubi P, Ayers-Ringler J, Rabbitt J, Page M, Fedoroff A, Sneed PK, Berger MS, Mcdermott MW, Parsa AT, Vandenberg S, James CD, Lamborn KR, Stokoe D, Haas-Kogan DA (2009) Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol 27:579–584

    Article  PubMed  CAS  Google Scholar 

  • Prados MD, Yung WK, Wen PY, Junck L, Cloughesy T, Fink K, Chang S, Robins HI, Dancey J, Kuhn J (2008) Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a north american brain tumor consortium study. Cancer Chemother Pharmacol 61:1059–1067

    Article  PubMed  CAS  Google Scholar 

  • Raizer JJ, Abrey LE, Lassman AB, Chang SM, Lamborn KR, Kuhn JG, Yung WK, Gilbert MR, Aldape KA, Wen PY, Fine HA, Mehta M, Deangelis LM, Lieberman F, Cloughesy TF, Robins HI, Dancey J, Prados MD (2001) A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neurooncol 12:95–103

    Google Scholar 

  • Reya T, Morrison SJ, Clarke MF, Weissman IL (2001) Stem cells, cancer, and cancer stem cells. Nature 414:105–111

    Article  PubMed  CAS  Google Scholar 

  • Rich JN, Reardon DA, Peery T, Dowell JM, Quinn JA, Penne KL, Wikstrand CJ, Van Duyn LB, Dancey JE, Mclendon RE, Kao JC, Stenzel TT, Ahmed Rasheed BK, Tourt-Uhlig SE, Herndon JE 2nd, Vredenburgh JJ, Sampson JH, Friedman AH, Bigner DD, Friedman HS (2004) Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 22:133–142

    Article  PubMed  CAS  Google Scholar 

  • Sharma PS, Sharma R, Tyagi T (2009) Receptor tyrosine kinase inhibitors as potent weapons in war against cancers. Curr Pharm Des 15:758–776

    Article  PubMed  CAS  Google Scholar 

  • Soeda A, Inagaki A, Oka N, Ikegame Y, Aoki H, Yoshimura S, Nakashima S, Kunisada T, Iwama T (2008) Epidermal growth factor plays a crucial role in mitogenic regulation of human brain tumor stem cells. J Biol Chem 283:10958–10966

    Article  PubMed  CAS  Google Scholar 

  • Stiles CD, Rowitch DH (2008) Glioma stem cells: a midterm exam. Neuron 58:832–846

    Article  PubMed  CAS  Google Scholar 

  • Stupp R, Mason WP, Van Den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996

    Article  PubMed  CAS  Google Scholar 

  • Van Den Bent MJ, Brandes AA, Rampling R, Kouwenhoven MC, Kros JM, Carpentier AF, Clement PM, Frenay M, Campone M, Baurain JF, Armand JP, Taphoorn MJ, Tosoni A, Kletzl H, Klughammer B, Lacombe D, Gorlia T (2009) Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J Clin Oncol 27:1268–1274

    Article  PubMed  Google Scholar 

  • Wang MY, Lu KV, Zhu S, Dia EQ, Vivanco I, Shackleford GM, Cavenee WK, Mellinghoff IK, Cloughesy TF, Sawyers CL, Mischel PS (2006) Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer Res 66:7864–7869

    Article  PubMed  CAS  Google Scholar 

  • Yarden Y (2001) The EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities. Eur J Cancer 37(Suppl 4):S3–S8

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratory of Pharmacology, Department of Oncology, Biology and Genetics, University of Genova, 16132, Genova, Italy

    Federica Barbieri, Adriana Bajetto, Alessandra Pattarozzi, Monica Gatti, Roberto Würth, Carola Porcile & Tullio Florio

  2. Department of Translational Oncology, National Institute for Cancer Research (IST), Genova, Italy

    Antonio Daga, Roberto E. Favoni & Giorgio Corte

Authors
  1. Federica Barbieri
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Adriana Bajetto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alessandra Pattarozzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Monica Gatti
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Roberto Würth
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Carola Porcile
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Antonio Daga
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Roberto E. Favoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Giorgio Corte
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Tullio Florio
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tullio Florio .

Editor information

Editors and Affiliations

  1. Dept. Biological Sciences, Kean University, 1000 Moris Avenue, Union, 07083, New Jersey, USA

    M. A. Hayat

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media B.V.

About this chapter

Cite this chapter

Barbieri, F. et al. (2011). Glioblastoma Cancer Stem Cells: Response to Epidermal Growth Factor Receptor Kinase Inhibitors. In: Hayat, M. (eds) Tumors of the Central Nervous System, Volume 1. Tumors of the Central Nervous System, vol 1. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-0344-5_22

Download citation

  • DOI: https://doi.org/10.1007/978-94-007-0344-5_22

  • Published:

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-007-0343-8

  • Online ISBN: 978-94-007-0344-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation